Cancer despite immunosurveillance: immunoselection and immunosubversion
The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cancers must escape from immunosurveillance to advance to a clinically detectable state, meaning that they either are passively selected to ''hide'' from immune recognition (immunoselection) or actively suppress immune effectors (immunosubversion).249”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [249]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“By contrast, it is thought that TGFβ can also have immunostimulatory effects (in particular, on specific T H -cell subset”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“More importantly, tryptophan degradation by indoleamine 2,3-dioxygenase ( IDO ), which is constitutively expressed by human tumours (particularly by prostate, colon and pancreatic carcinomas, but also by interdigitating DCs), promotes resistance to immune-mediated rejection of the tumour cell”
BackgroundImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Items 801–900 of 1,000
Metronomic chemotherapy in ovarian cancer
Garg, V., & Kumar, L. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216469 · Cited by 12
The Role of Natural Killer Cells in Oncolytic Virotherapy: Friends or Foes?
Franks, M. L., An, J.-H., & Leavenworth, J. W. (2024) · Vaccines · doi:10.3390/vaccines12070721 · Cited by 14
Apétoh, L., Ghiringhelli, F., & Zitvogel, L. (2007) · médecine/sciences · doi:10.1051/medsci/2007233257 · Cited by 15
“Cependant, afin d’éliminer les cellules tumorales résiduelles résistantes à ce traitement et les cellules souches cancéreuses, l’induction d’une mort cellulaire « immunogène », c’est-à-dire capable de déclencher une réponse immunitaire de l’hôte contre sa propre tumeur, est également un objectif des traitements antica…”
The role of pembrolizumab in the treatment of advanced non-small cell lung cancer
Santabarbara, G., Maione, P., Rossi, A., Palazzolo, G., & Gridelli, C. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.05.64 · Cited by 11
“, interleukin-10, transforming growth factor-α) and cellular immune dysfunction through modulation of immune checkpoint pathways (9,13-16).”
BackgroundBastin, D. J., Walsh, S. R., Saigh, M. A., & Wan, Y. (2016) · Biomedicines · doi:10.3390/biomedicines4030021 · Cited by 17
“In the past decade it has become widely appreciated that cancer becomes clinically apparent when the disease has acquired the capacity to evade immune detection or locally dampen the immune response [31].”
BackgroundWei, B., Ruan, J., Mi, Y., Hu, J., Zhang, J., Wang, Z., Hu, Q., Jiang, H., & Ding, Q. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.145 · Cited by 14
Tissue-resident lymphocytes: weaponized sentinels at barrier surfaces
Belz, G. T., Denman, R., Seillet, C., & Jacquelot, N. (2020) · F1000Research · doi:10.12688/f1000research.25234.1 · Cited by 12
Bastin, D. J., Khan, S., Montroy, J. R., Kennedy, M. A., Forbes, N. E., Martel, A. B., Baker, L. K., Gresham, L. M., Boucher, D. M., Wong, B., et al. (2021) · Hematological Oncology · doi:10.1002/hon.2875 · Cited by 19
“In contrast, whole cell cancer vaccines are antigen agnostic and better suited to stimulating a polyclonal response that may be less susceptible to cancer escape following immune editing.(5,6) A retrospective analysis of 173 studies and over 3000 patients revealed that those receiving either whole tumor cells or tumor…”
BackgroundInfluentialCurrent Advancements and Future Perspectives of Immunotherapy in Breast Cancer Treatment
Vasileiou, M., Papageorgiou, S., & Nguyen, N. P. (2023) · Immuno · doi:10.3390/immuno3020013 · Cited by 15
“Next, tumor cells that survive the elimination phase, enter a state of equilibrium, which is a transition period from the elimination phase to the onset of the disease [6].”
BackgroundRadical Tumor Denervation Activates Potent Local and Global Cancer Treatment
Mitsou, J. D., Tseveleki, V., Dimitrakopoulos, F.-I. D., Konstantinidis, K. M., & Kalofonos, H. P. (2023) · Cancers · doi:10.3390/cancers15153758 · Cited by 16
“Moreover, the contribution of sympathetic innervation to the formation of distant metastatic foci in breast cancer has been highlighted, and the remarkable ability of adrenergic signaling to modulate bone vasculature, driving breast cancer cell engraftment in the bone niche, has been addressed [85].”
BackgroundChronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging, or Vice Versa?
Sharp, Z. D., Curiel, T. J., & Livi, C. B. (2013) · Interdisciplinary topics in gerontology and geriatrics · doi:10.1159/000343625 · Cited by 12
Oxysterols recruit tumor-supporting neutrophils within the tumor microenvironment
Raccosta, L., Fontana, R., Traversari, C., & Russo, V. E. A. (2013) · OncoImmunology · doi:10.4161/onci.26469 · Cited by 12
Increased percentage of B cells in patients with more advanced hepatocellular carcinoma
Lin, J.-C., Shih, Y., Chien, P.-J., Liu, C., Lee, J.-J., Liu, T.-P., Ko, W.-C., & Shih, C.-M. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.10.003 · Cited by 12
Different expression of MAGE-A-antigens in foetal and adult keratinocyte cell lines
Müller-Richter, U. D. A., Dowejko, A., Weiqi, Z., Reichert, T. E., & Driemel, O. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2007.08.007 · Cited by 12
Immunopathology and Immunomodulation
Metodiev, K. (2015) · InTech eBooks · doi:10.5772/59217 · Cited by 15
Gasparri, M. L., Ruscito, I., Taghavi, K., Farooqi, A. A., Papadia, A., Focaccetti, C., Barnaba, V., Panici, P. B., & Mueller, M. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-53082-6_9 · Cited by 26
Bala, A., & Panditharadyula, S. S. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190705205155 · Cited by 12
CCL25 Signaling in the Tumor Microenvironment
Mir, H., & Singh, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-62658-7_8 · Cited by 13
Chan, M., Wu, L., Yun, Z., McKee, T. D., Cabanero, M., Zhao, Y. D., Kohno, M., Murakami, J., & de Perrot, M. E. (2021) · Communications Biology · doi:10.1038/s42003-021-02430-5 · Cited by 12
Che, X., Su, W., Li, X., Liu, N., Wang, Q., & Wu, G. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.731214 · Cited by 15
van den Ancker, W., van Luijn, M. M., Chamuleau, M. E. D., Kelder, A., Feller, N., Terwijn, M., Zevenbergen, A., Schuurhuis, G., van Ham, S. M., Westers, T. M., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.014 · Cited by 11
Langhammer, S. (2013) · Oncology Reports · doi:10.3892/or.2013.2631 · Cited by 11
“In HIV infections and in tumor development, these mechanisms include the generation of escape mutants and the suppression of the immune system (43,48-54).”
BackgroundPerspective on Translating Biomaterials Into Glioma Therapy: Lessons From in Vitro Models
Cornelison, R. C., & Munson, J. M. (2018) · Frontiers in Materials · doi:10.3389/fmats.2018.00027 · Cited by 14
“Early in tumor development, anti-inflammatory cytokines enable tumor cells to evade the host immune response (Zitvogel et al., 2006; Razavi et al., 2016).”
BackgroundCui, Y., Yu, S., Zhu, M., Cheng, X., Yu, Y., Tang, Z., Wang, X., Hou, J., Hou, Y., Ren, D., et al. (2019) · Journal of Cancer · doi:10.7150/jca.38536 · Cited by 11
“Although these treatments can control many primary tumors effectively, but they offer little in terms of survival benefits in curbing the metastatic spread of cancer cells due to its heterogeneous nature and the ability to evade cell death[1] and to escape immune system surveillance[2].”
BackgroundLiposomes targeting tumour stromal cells
Kuijpers, S. A., Coimbra, M., Storm, G., & Schiffelers, R. M. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.522204 · Cited by 11
“In general, however, immunosurveillance seems important in eliminating early-stage transformed cells, whereas clinically advanced tumours are able to avoid immunosurveillance by inducing immune tolerance (Zitvogel et al. 2006).”
BackgroundWang, B., Zhu, J., Ma, X., Qiu, S., Pan, B., Zhou, J., Fan, J., Yang, X., & Guo, W. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.10.017 · Cited by 13
Natural killer cell-based strategies for immunotherapy of cancer
Vaněk, O., Kalousková, B., Abreu, C., Nejadebrahim, S., & Skořepa, O. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.02.001 · Cited by 12
Rossignol, J., Belaid, Z., Fouquet, G., Guillem, F., Rignault, R., Milpied, P., Renand, A., Coman, T., D'Aveni, M., Dussiot, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104353 · Cited by 8
“These checkpoints are involved in immune escape of cancer cells and are responsible for T cell exhaustion in the tumor environment (Zitvogel et al., 2006).”
BackgroundNabors, B., Lamb, L. S., Goswami, T., Rochlin, K. M., & Youngblood, S. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1299044 · Cited by 14
Multifaceted Kinetics of Immuno-Evasion from Tumor Dormancy
d’Onofrio, A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-1445-2_7 · Cited by 13
Mantzaris, G. J. (2014) · Digestive Diseases · doi:10.1159/000367862 · Cited by 11
Kobayashi, N., Hong, C., Klinman, D. M., & Shirota, H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201063 · Cited by 11
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors.
Heiblig, M., Elhamri, M., Michallet, M., & Thomas, X. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i7.1022 · Cited by 14
Enriched environment enhances NK cell maturation through hypothalamic BDNF in male mice
Mansour, A. G., Xiao, R., Bergin, S. M., Huang, W., Chrislip, L. A., Zhang, J., Ali, S., Queen, N. J., Caligiuri, M. A., & Cao, L. (2021) · European Journal of Immunology · doi:10.1002/eji.201948358 · Cited by 14
Zuin, J., Veggiani, G., Pengo, P., Gallotta, A., Biasiolo, A., Tono, N., Gatta, A., Pontisso, P., Toth, R., Cerin, D., et al. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.044 · Cited by 11
“Clin Chem Lab Med 2010;48(2):217–223 2010 by Walter de Gruyter • Berlin • New York.”
BackgroundReig, M., Gazzola, A., Donato, R. D., & Bruix, J. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.08.003 · Cited by 11
Meirelles, A. L. S., Kurç, T., Kong, J., Ferreira, R., Saltz, J. H., & Teodoro, G. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.894430 · Cited by 15
“Multiple studies have shown that there is a correlation between the density and spatial organization of TILs and clinical outcomes (37, 38, 56, 57).”
BackgroundThe role of IL-37 in gastrointestinal diseases
Wang, Q., Zhang, G., An, C., Hambly, B. D., & Bao, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1431495 · Cited by 14
Synthetic and biological nanoparticles for cancer immunotherapy
Oliveira, I., Rodrigues‐Santos, P., Ferreira, L., & das Neves, R. P. (2024) · Biomaterials Science · doi:10.1039/d4bm00995a · Cited by 10
Wu, J., Zhang, L., Zhao, Z., Liu, Y., Li, Z., Feng, X., Zhang, L., Yao, X., Du, J., Chen, L., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102783 · Cited by 10
Chenevix‐Trench, G., Lei, J., kConFab Investigators, Rudolph, A., Moysich, K. B., Behrens, S., Goode, E. L., Bolla, M. K., Dennis, J., Dunning, A. M., et al. (2015) · Human Genetics · doi:10.1007/s00439-015-1616-8 · Cited by 10
“…Krieg and Boyman 2009; Mills 2004; Ostrand-Rosenberg 2008; Poschke et al. 2011; Sakaguchi et al. 2013; Sica et al. 2008; Wilczynski and Duechler 2010; Zitvogel et al. 2006; Zou 2005), using the search terms ‘‘immunosuppression’’/‘‘immunosuppressive’’, ‘‘regulatory T cells’’/‘‘Treg cells’’/‘‘FOXP3?”
Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer
Grundy, M., Coussios, C. C., & Carlisle, R. C. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1167036 · Cited by 11
Lee, S. F., Yip, P. L., Wong, A., Ng, F., Koh, V., Wong, L. C., Luk, H., Ng, C. K., Lee, F. A. S., & Mamon, H. J. (2022) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2022.07.007 · Cited by 11
“The association between lymphopenia and inferior survival outcomes supports that the immune system contributes to tumor control [33].”
BackgroundMicroRNAs affecting the susceptibility of melanoma cells to CD8+ T cell‐mediated cytolysis
Pane, A. A., Kordaß, T., Hotz‐Wagenblatt, A., Dickes, E., Kopp‐Schneider, A., Will, R. D., Seliger, B., Osen, W., & Eichmüller, S. B. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1186 · Cited by 9
Sarfraz, Z., Sarfraz, A., Farooq, M. D., Khalid, M., Cheema, K., Javad, F., Khan, T., Pervaiz, Z., Sarfraz, M., Jaan, A., et al. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01078-8 · Cited by 11
Paco, L., Garcia-Lora, A. M., Casares, C., Cabrera, C., Algarra, I., Collado, A., Maleno, I., Garrido, F., & López‐Nevot, M. Á. (2007) · International Journal of Cancer · doi:10.1002/ijc.22925 · Cited by 10
“At early stages, specific autologous immune response can select tumor cells with one HLA haplotype loss(11,35) that are then immune-tolerant.(36) In a second stage of tumor progression, variants with total loss of HLA class I expression appear and predominate without immunoselection because they present a more aggress…”
BackgroundWu, H., Yu, H., Ye, Q., Cao, C., XIA, Y., Liu, C.-B., & Wang, Y. (2012) · Oncology Reports · doi:10.3892/or.2012.2142 · Cited by 11
“Therefore, a method that can induce the immunogenic transformation of tumour cells and restore the body's immune response against tumour cells could represent an effective pathway for tumour prevention and therapy (1).”
Immunotherapy in Acute Leukemia
Leung, W. H. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.09.004 · Cited by 11
Senescence and Senescence-Related Disorders
Wang, Z. P., & Inuzuka, H. (2013) · InTech eBooks · doi:10.5772/56158 · Cited by 12
Li, M., Bai, J., Wang, S., Zhai, Y., Zhang, S., Li, C., Du, J., & Zhang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s257779 · Cited by 10
Chen, W., Liu, W., Li, Y., Wang, J., Ren, Y., Wang, G., Chen, C., & Li, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.716042 · Cited by 10
Immune Compartmentalization of T cell Subsets in Chemically‐induced Breast Cancer
Fahmi, T., Esendağlı, G., Yilmaz, G., Kansu, E., & Guc, D. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02447.x · Cited by 10
Antitumor effects of sulfated polysaccharides produced from marine algae
Zaporozhets, T. S., Ermakova, S. P., Николаевна, З. Т., & Besednova, N. N. (2014) · Biology Bulletin Reviews · doi:10.1134/s2079086414020078 · Cited by 10
“…is realized with Th1 dependent, and, to a lesser extent, Th2 dependent, immune responses (Dunn et al., 2002, 2004; Hanahan and Weinberg, 2000; Zitvogel et al., 2006; Kim et al., 2007), as well as innate factors of immunity damaging tumor cells (NK cells, monocytes/macrophages, α and β…”
BackgroundVeillet, A. L., Haag, J. D., Remfert, J. L., Meilahn, A. L., Samuelson, D. J., & Gould, M. N. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0187 · Cited by 11
“The significance of ovarian hormones and the immune system on human breast cancer has also been described (29, 30).”
BackgroundJajosky, A. N., Coad, J. E., Vos, J. A., Martin, K. H., Senft, J. R., Wenger, S. L., & Gibson, L. F. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0193 · Cited by 11
Li, B., Yang, L., Wang, X., Yan, Z., Liu, H., Liu, G., & Liu, S. (2015) · Europe PMC (PubMed Central) · Cited by 11
Intrinsic Control of Surface Immune and Epithelial Homeostasis by Tissue-Resident Gut Stromal Cells
Kurashima, Y., Tokuhara, D., Kamioka, M., Inagaki, Y., & Kiyono, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01281 · Cited by 12
Cross-Cancer Pleiotropic Analysis Reveals Novel Susceptibility Loci for Lung Cancer
Wang, L., Zhu, M., Wang, Y., Fan, J., Sun, Q., Ji, M., Fan, X., Xie, J., Dai, J., Jin, G., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01492 · Cited by 12
“This variant was related to the expression of MICA, a stress-induced gene expressed by cancer cells, function as ligands for NKG2D receptors (36).”
BackgroundDendritic cells: still a promising tool for cancer immunotherapy
Aragoneses-Fenoll, L., & Corbí, A. L. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0016-5 · Cited by 10
“However, and in spite of the various immune mechanisms for recognition and elimination of transformed cells, tumour cells manage to escape from immunosurveillance though a combination of immunoselection and immunosubversion strategies [ 13 ].”
BackgroundDisarming dendritic cells: a tumor strategy to escape from immune control?
Bella, S. D., Clerici, M., & Villa, M. L. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.3.411 · Cited by 10
Design of Cell-Specific Targeting Peptides for Cancer Therapy
Chen, X., Wang, D., Jiang, Y., & Jiang, T. (2024) · Targets · doi:10.3390/targets2030011 · Cited by 12
“Cancer cells possess oncogenic aberrations that promote abnormal proliferation, migration, and the evasion of immune surveillance [28,29].”
BackgroundWatanabe, A., Hara, M., Chosa, E., Nakamura, K., Sekiya, R., Shimizu, T. M., & Onitsuka, T. (2009) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923970903222355 · Cited by 9
“Foxp3CD25CD4 regulatory T (Treg) cells play a major role in tumor-related immune suppression [3].”
BackgroundEffects of lung cancer cell-associated B7-H1 on T-cell proliferation in vitro and in vivo
Chen, K., Huang, H.-H., Hang, W.-H., Pan, L., & Ma, H. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165263 · Cited by 9
Prediction of optimal gene functions for osteosarcoma using gene ontology and microarray profiles
Chen, X.-R. (2017) · Journal of bone oncology · doi:10.1016/j.jbo.2017.04.003 · Cited by 10
“During the tumor occurrence and metastasis, cancer cells can modulate the immune system of the host to find strategies that enable them to survive from the immune surveillance [41].”
BackgroundRegulation of immunological tolerance by the p53-inhibitor iASPP
Akama‐Garren, E. H., Miller, P., Carroll, T. M., Tellier, M., Sutendra, G., Buti, L., Zaborowska, J., Goldin, R. D., Slee, E. A., Szele, F. G., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05567-9 · Cited by 12
Clec4A4 Acts as a Negative Immune Checkpoint Regulator to Suppress Antitumor Immunity
Uto, T., Fukaya, T., Mitoma, S., Nishikawa, Y., Tominaga, M., Choijookhuu, N., Hishikawa, Y., & Sato, K. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0536 · Cited by 10
Kuehn, F., Mullins, C. S., Krohn, M., Harnack, C., Ramer, R., Krämer, O. H., Klar, E., Hühns, M., & Linnebacher, M. (2016) · Scientific Reports · doi:10.1038/srep24671 · Cited by 9
Minkov, P., Gulubova, M. V., Ivanova, K. V., Obretenov, E., & Ananiev, J. R. (2019) · Polish Journal of Pathology · doi:10.5114/pjp.2019.87102 · Cited by 9
Extracellular Vesicles in Cancer Progression: Are They Part of The Problem or Part of The Solution?
Scholl, J. N., Dias, C. K., Müller, L., Battastini, A. M. O., & Figueiró, F. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0256 · Cited by 12
Targeting the Tumor Microenvironment of Ewing Sarcoma
Morales, E., Olson, M., Cardenas, F. I., Luetkens, T., & Atanackovic, D. (2021) · Immunotherapy · doi:10.2217/imt-2020-0341 · Cited by 11
Hamidinia, M., Boroujerdnia, M. G., Talaiezadeh, A., Solgi, G., Taghdiri, M., & Khodadadi, A. (2013) · PubMed · doi:10.22034/iji.2013.16800 · Cited by 9
Donati, G., D’Amore, V. M., Russomanno, P., Cerofolini, L., Amato, J., Marzano, S., Salobehaj, M., Rizzo, D., Assoni, G., Carotenuto, A., et al. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.06.006 · Cited by 9
“[3,4] On the other hand, the overexpression of their ligands on cancer cells allows the tumor to evade the immune surveillance [5,6].”
BackgroundTumor Microenvironment and the Immune Response
Selleri, S., Rumio, C., Sabatino, M., Marincola, F. M., & Wang, E. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.002 · Cited by 9
Günaydın, R. Ö., Kesikli, S. A., Kansu, E., & Hoşal, A. Ş. (2011) · Head & Neck · doi:10.1002/hed.21738 · Cited by 9
“The immune system is able to recognize precursor tumor cells and, in most cases, destroys these precursors before the onset of clinical disease, a process known as cancer immunosurveillance.(31) CD8þ cytotoxic T lymphocytes, activated CD4þ T-cells, IFNcproducing killer dendritic cells, natural killer T-cells, NK cells…”
BackgroundIntegrative oncology: the last ten years--a personal retrospectve.
Boyd, D. B. (2007) · PubMed · Cited by 10
Lin, Y., Lin, L., Hang, J., Lin, C., Ho, H., & Chou, T. (2020) · Cancer Cytopathology · doi:10.1002/cncy.22359 · Cited by 9
“Despite expressing potential antigens such as mutated proteins, tumor cells are known to utilize a variety of methods to avoid being killed by immune cells.(1) One such mechanism involves hijacking the “immune checkpoint” system, which normally turns down an immune response when an inflammatory process has already eli…”
BackgroundMacrophage-mediated immunoediting drives ductal carcinoma evolution: Space is the game changerPreprint
Gatenbee, C., West, J., Baker, A. M., Guljar, N., Jones, J. L., Graham, T. A., Robertson‐Tessi, M., & Anderson, A. R. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/594598 · Cited by 9
Papachristos, A., Serrao-Brown, H. G., Gill, A. J., Clifton-Bligh, R. J., & Sidhu, S. B. (2024) · Cancers · doi:10.3390/cancers16132296 · Cited by 10
“This escape from immune surveillance may be considered the ‘seventh hallmark’ of cancer [39], and similarly, the vigour of the immune response to genetically altered tissue has been demonstrated to be a prognostic factor for survival in melanoma [40], colorectal, breast and ovarian cancer [38].”
BackgroundImmune predictors of cancer progression
Toh, B., Chew, V., Dai, X., Khoo, K., Tham, M., Wai, L., Hubert, S., Velumani, S., Zhi, L., Huang, C. W., et al. (2012) · Immunologic Research · doi:10.1007/s12026-012-8288-4 · Cited by 8
Glinka, J., Ardiles, V., Pekolj, J., Mattera, J., Clariá, R. S., de Santibáñes, E., & de Santibañes, M. (2020) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-020-01883-2 · Cited by 8
Comprehensive Analysis of Regulatory Network for LINC00472 in Clear Cell Renal Cell Carcinoma
Gao, S., & Wang, Z. (2021) · Journal of Healthcare Engineering · doi:10.1155/2021/3533608 · Cited by 9
“Tumor cells escape through a variety of mechanisms, including low expression of tumor surface antigens, making it difficult for the immune system to monitor them; the secretion of immunosuppressive factors (such as transforming growth factor beta, interleukin-10) and different regulation and induction of sexual lympho…”
BackgroundRetractedWang, S., Onyeaghala, G. C., Pankratz, N., Nelson, H. H., Thyagarajan, B., Tang, W., Norby, F. L., Ugoji, C. C., Joshu, C. E., Gómez, C. R., et al. (2023) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-22-1113 · Cited by 7
Park, J., Kim, J. C., Lee, M., Lee, J., Kim, Y., Lee, Y. J., Kim, S. W., Kim, S. W., Park, S., & Lee, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02455-z · Cited by 8
Cell-mediated barriers in cancer immunosurveillance
Rezaie, J., Chodari, L., Mohammadpour-Asl, S., Jafari, A., & Niknam, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122528 · Cited by 11
Nedelkovska, H., & Robert, J. (2013) · Europe PMC (PubMed Central) · Cited by 8
Cho, J. S., Park, M. H., Lee, J. S., & Yoon, J. H. (2014) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000041 · Cited by 8
HNSCC subverts PBMCs to secrete soluble products that promote tumor cell proliferation
de Medeiros, M. C., Banerjee, R., Liu, M., Anovazzi, G., D’Silva, N. J., & Rossa, C. (2017) · Oncotarget · doi:10.18632/oncotarget.18486 · Cited by 12
“Thus, HNSCC subverts immune cells to favor tumor growth (‘immunosubversion’) [70].”
BackgroundFragiadakis, G. K., Bjornson, Z. B., Madhireddy, D., Sachs, K., Chen, H. M., McIlwain, D. R., Spitzer, M. H., Bendall, S. C., & Nolan, G. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867016 · Cited by 13
Cancer vaccines: Where are we going?
Cebon, J. S. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01270.x · Cited by 8
Lee, C.-H., Chiang, Y., Chang, S., Chong, C.-L., Cheng, B.-M., & Roffler, S. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2311 · Cited by 8
Gertner-Dardenne, J., Scotet, E., Poupot, M., Bonneville, M., & Fournié, J. (2007) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0001195.pub2 · Cited by 8
Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches
Amin, T., Hossain, A., Jerin, N., Mahmud, I., Rahman, M. A., Islam, S. M. R., & Islam, S. M. B. U. (2024) · Cancer Control · doi:10.1177/10732748241290067 · Cited by 10
“73 This allows them to avoid immune system assault.”
BackgroundEndogenous retroviruses in aging and cancer: from genomic defense to oncogenic activation
dos Santos, G. A., D’Alessandre, N. D. R., Guardia, G. D. A., Batista, R. L., & Galante, P. A. F. (2025) · Mobile DNA · doi:10.1186/s13100-025-00383-8 · Cited by 7
“Specifically, studies have indicated that ERVs can activate the innate immune system, primarily through the presence of ERV-derived cytoplasmic nucleic acids and ERV-like proteins [177, 178].”
Zeng, R., Li, Y., He, D.-M., Sun, M.-Z., Huang, W., Wang, Y., Zhuo, Y., Chen, J.-J., Chen, T., Guo, J.-H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1013324 · Cited by 8
Tominaga, M., Uto, T., Fukaya, T., Mitoma, S., Riethmacher, D., Umekita, K., Yamashita, Y., & Sato, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1200461 · Cited by 7
Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy
Wilson, K. D., & Tam, Y. K. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2.2.181 · Cited by 7
The possible role of SRMS in colorectal cancer by bioinformatics analysis
Zhang, J., Liu, W., Feng, S., & Zhong, B. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02431-y · Cited by 8
“Tumor cells utilize various immune escape mechanisms, creating a microenvironment that is favorable for tumor growth and metastasis [44].”
BackgroundA proposal for a simple and inexpensive therapeutic cancer vaccine
Fahrer, A. M. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.42 · Cited by 7
Tumor-targeting CTL expressing a single-chain Fv specific for VEGFR2
Kanagawa, N., Yanagawa, T., Mukai, Y., Yoshioka, Y., Okada, N., & Nakagawa, S. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.085 · Cited by 7
“TCR gene-modified T cells were generated previously [8,9].”
BackgroundInfluentialCD8+ lymphocytes and apoptosis in typical and atypical medullary carcinomas of the breast
Nurlaila, I., Telisinghe, P. U., & Ramasamy, R. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.10.001 · Cited by 7
Metadata
- Authors
- Zitvogel, L., Tesniere, A., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature reviews. Immunology
- Published
- 2006-09-15
- Volume
- 6
- Issue
- 10
- Pages
- 715-727
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063192133
- Cited by
- 1,324
- References
- 127
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 62 · 2023: 75 · 2022: 68 · 2021: 63 · 2020: 63 · 2019: 60 · 2018: 66 · 2017: 76 · 2016: 72 · 2015: 81 · 2014: 87 · 2013: 89 · 2012: 82
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Conseil Régional, Île-de-France
- Institut National Du Cancer
- Cancéropôle Ile de France
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor surveillance, immunoselection, tumor immunogenicity, antitumor immunity, carcinogenesis, immunogenic chemotherapy
- MeSH terms
- Animals, Humans, Immune Tolerance, Immunologic Surveillance, Neoplasms, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.